http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Coexistence of osteoporosis, sarcopenia and obesity in community-dwelling adults – The Yishun Study
Benedict Wei Jun Pang,Shiou-Liang Wee,Kenneth Kexun Chen,Lay Khoon Lau,Khalid Abdul Jabbar,Wei Ting Seah,Daniella Hui Min Ng,Queenie Lin Ling Tan,Mallya Ullal Jagadish,Tze Pin Ng 대한골다공증학회 2021 Osteoporosis and Sarcopenia Vol.7 No.1
Objectives: To 1) report prevalence of ‘osteosarcopenia’ (OS) and osteosarcopenic obesity (OSO) entities using evidence-based diagnostic techniques and definitions, 2) examine if OSO offers additional predictive value of functional decline over its components, and 3) identify associated factors in a multi-racial Southeast Asian population. Methods: We performed a cross-sectional study of a representative sample of 542 community-dwelling adults (21e90 years old), and assessed anthropometry, cognition, functional performance, and selfreport sociodemographic, health and lifestyle questionnaires. Low muscle mass, and the Asian Working Group for Sarcopenia (AWGS) 2019 criteria, were used to assess sarcopenia. Obesity was defined using percentage body fat and fat mass index. Osteopenia/osteoporosis was determined using lumbar spinal bone mineral density. Associated factors were examined using logistic regression, and OSO’s value investigated using linear regressions with functional performance. Results: OS and OSO prevalence were 1.8% and 0% (21e59 years), 12.9% and 2.8% ( 60 years), 17.3% and 4.1% ( 65 years), and 25.5% and 7.0% (75 years), respectively. OSO entity as defined was not a significant predictor (P > 0.05) and did not improve explanations for functional decline over sarcopenia or sarcopenic obesity. Age, sex, race and body mass index (BMI) were associated with OS, while age, sex, race and alcoholism were associated with OSO. Conclusions: Our results do not support OSO as a distinct entity in relation to functional decline. Aside from biological age, sex, and race, amenable lifestyle factors such as BMI and alcohol intake are important variables that can influence the co-existence of osteopenia/osteoporosis, sarcopenia and obesity.
Choon Jin Ooi,Ida Hilmi,Rupa Banerjee,Sai Wei Chuah,Siew Chien Ng,Govind K Makharia,Pises Pisespongsa,Min Hu Chen,Zhi Hua Ran,Byong Duk Ye,Dong Il Park,Khoon Lin Ling,David Ong,Vineet Ahuja,Khean Lee 대한장연구학회 2019 Intestinal Research Vol.17 No.3
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn’s and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn’s disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.